Product Data: Total Proinsulin Chemiluminescence ELISA
ALPCO’s Total Proinsulin Chemiluminescence ELISA offers excellent sensitivity and the greatest dynamic range on the
market.
ALPCO’s Total Proinsulin Chemiluminescence ELISA offers excellent sensitivity and the greatest dynamic range on the
market.
ALPCO’s Active GLP-1 (7-36) amide Chemiluminescence ELISA accurately measures the major biologically active circulating form of GLP-1.1,2 This well-characterized assay provides high analytical sensitivity, a short incubation time, and measures active GLP-1 (7-36) amide in fasted and fed samples.
The STELLUX® Rodent Insulin ELISA provides the flexibility to run both mouse and rat samples on the same plate with minimal to no dilution and a short two hour incubation.
ALPCO’s Insulin Chemiluminescence ELISA detects insulin at levels as low as 20 pg/mL in human serum, plasma, and β-islet tissue culture supernatants, without cross-reactivity to human intact proinsulin, mouse insulin, or rat insulin.
ALPCO's STELLUX® Chemi Active GLP-1 (7-36) Amide ELISA provides accurate quantification and resolves sample size and analytical performance issues.
This infographic distills the essence of the new American Gastroenterological Association (AGA) Clinical Practice Guideline on the Role of Biomarkers in Crohn's Disease (CD). It sheds light on the nuanced recommendations for using biomarkers to monitor and evaluate CD, emphasizing their value in conjunction with clinical symptoms.
In honor of scientists and researchers in the field of diabetes, we've compiled a partial list of their 2023 published work. These publications aren't just studies; they're milestones on the path to a healthier future, made possible by their dedication.
What makes this list so special to ALPCO? It's a testament to how our products empower these tireless champions in their quest for discoveries and breakthroughs in diabetes research.
In an effort to improve patient care, an increasing number of gastroenterologists are using fecal calprotectin levels as a first step in the diagnosis of IBD versus IBS. ALPCO tests enable clinicians to accurately assess patients via calprotectin and quickly start patients on the right treatment path.
ALPCO’s automated multiplex assay, AutoPlex GI Panel, provides sensitive and accurate measurement of up to 5 GI biomarkers in human stool samples. The panel combines the workflow advantages of multiplexing with the proven reliability of traditional chemiluminescence sandwich immunoassays to enable batched sample processing for related biomarkers.